Peringatan Keamanan

Data regarding acute overdoses of glucocorticoids are rare.L15047,L15052 Chronic high doses of glucocorticoids can lead to the development of cataract, glaucoma, hypertension, water retention, hyperlipidemia, peptic ulcer, pancreatitis, myopathy, osteoporosis, mood changes, psychosis, dermal atrophy, allergy, acne, hypertrichosis, immune suppression, decreased resistance to infection, moon face, hyperglycemia, hypocalcemia, hypophosphatemia, metabolic acidosis, growth suppression, and secondary adrenal insufficiency.A188405 Overdose may be treated by adjusting the dose or stopping the corticosteroid as well as initiating symptomatic and supportive treatment.A188405,L15102

Ulobetasol

DB00596

small molecule approved

Deskripsi

Ulobetasol is a highly potent corticosteroid.A215597 It is structurally related to clobetasol.A215597 Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses.L15047,L15052,L15102

Ulobetasol was granted FDA approval on 17 December 1990.L15047

Struktur Molekul 2D

Berat 428.9
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) _In vitro_ experiments show halobetasol propionate, a derivative of ulobetasol, has a half life of 33 minutes.[L15097]
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Ulobetasol lotion reaches a Cmax of 201.1 ± 157.5 pg/mL, with a Tmax of 3 hours, and an AUC of 1632 ± 1147 pg\*h/mL.L15052 Absorption can be influenced by skin integrity, the vehicle used, inflammation, or disease processes.L15047,L15052

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Corticosteroids are eliminated predominantly in the urine.A187436

Interaksi Obat

138 Data
Trastuzumab The risk or severity of neutropenia can be increased when Trastuzumab is combined with Ulobetasol.
Tacrolimus Tacrolimus may increase the immunosuppressive activities of Ulobetasol.
Phenylephrine The risk or severity of hypertension can be increased when Ulobetasol is combined with Phenylephrine.
Aminoglutethimide The therapeutic efficacy of Ulobetasol can be decreased when used in combination with Aminoglutethimide.
Insulin human The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Insulin human.
Insulin lispro The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Insulin lispro.
Insulin glargine The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Insulin glargine.
Insulin pork The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Insulin pork.
Troglitazone The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Troglitazone.
Glimepiride The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Glimepiride.
Sulfisoxazole The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Sulfisoxazole.
Disopyramide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Disopyramide.
Acarbose The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Acarbose.
Metformin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Metformin.
Sulfadiazine The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Sulfadiazine.
Rosiglitazone The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Rosiglitazone.
Acetohexamide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Acetohexamide.
Quinine The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Quinine.
Miglitol The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Miglitol.
Chlorpropamide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Chlorpropamide.
Nateglinide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Nateglinide.
Pentamidine The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Pentamidine.
Mifepristone The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Mifepristone.
Tolazamide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Tolazamide.
Repaglinide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Repaglinide.
Phenformin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Phenformin.
Sulfamethoxazole The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Sulfamethoxazole.
Glyburide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Glyburide.
Glipizide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Glipizide.
Gliclazide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Gliclazide.
Tolbutamide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Tolbutamide.
Pioglitazone The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Pioglitazone.
Bromocriptine The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Bromocriptine.
Gliquidone The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Gliquidone.
Mitiglinide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Mitiglinide.
Sitagliptin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Sitagliptin.
Sunitinib The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Sunitinib.
Exenatide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Exenatide.
Mecasermin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Mecasermin.
Pramlintide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Pramlintide.
Glisoxepide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Glisoxepide.
Insulin aspart The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Insulin aspart.
Insulin detemir The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Insulin detemir.
Insulin glulisine The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Insulin glulisine.
Glymidine The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Glymidine.
AICA ribonucleotide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with AICA ribonucleotide.
Buformin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Buformin.
Vildagliptin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Vildagliptin.
Voglibose The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Voglibose.
NN344 The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with NN344.
AMG-222 The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with AMG-222.
Bisegliptin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Bisegliptin.
Alogliptin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Alogliptin.
Dapagliflozin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Dapagliflozin.
Saxagliptin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Saxagliptin.
Liraglutide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Liraglutide.
Gosogliptin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Gosogliptin.
Linagliptin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Linagliptin.
Canagliflozin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Canagliflozin.
Glibornuride The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Glibornuride.
Benfluorex The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Benfluorex.
Empagliflozin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Empagliflozin.
Albiglutide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Albiglutide.
Dulaglutide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Dulaglutide.
Lobeglitazone The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Lobeglitazone.
Netoglitazone The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Netoglitazone.
Rivoglitazone The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Rivoglitazone.
Ciglitazone The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Ciglitazone.
Lixisenatide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Lixisenatide.
Insulin beef The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Insulin beef.
Insulin degludec The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Insulin degludec.
Insulin peglispro The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Insulin peglispro.
Insulin tregopil The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Insulin tregopil.
Ipragliflozin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Ipragliflozin.
Dutogliptin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Dutogliptin.
Allicin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Allicin.
Tofogliflozin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Tofogliflozin.
Ertugliflozin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Ertugliflozin.
2,4-thiazolidinedione The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with 2,4-thiazolidinedione.
Teneligliptin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Teneligliptin.
Omarigliptin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Omarigliptin.
Carmegliptin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Carmegliptin.
Gemigliptin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Gemigliptin.
Anagliptin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Anagliptin.
Evogliptin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Evogliptin.
Sotagliflozin The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Sotagliflozin.
Balaglitazone The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Balaglitazone.
Remogliflozin etabonate The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Remogliflozin etabonate.
Carbutamide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Carbutamide.
Guar gum The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Guar gum.
Metahexamide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Metahexamide.
Semaglutide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Semaglutide.
Taspoglutide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Taspoglutide.
Englitazone The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Englitazone.
Tirzepatide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Tirzepatide.
Gastric inhibitory polypeptide The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Gastric inhibitory polypeptide.
Isoniazid The serum concentration of Isoniazid can be decreased when it is combined with Ulobetasol.
Cyclosporine The risk or severity of adverse effects can be increased when Ulobetasol is combined with Cyclosporine.
Digoxin The risk or severity of adverse effects can be increased when Ulobetasol is combined with Digoxin.
Acetyldigitoxin The risk or severity of adverse effects can be increased when Ulobetasol is combined with Acetyldigitoxin.

Target Protein

Steroid hormone receptor ERR1 ESRRA
Steroid hormone receptor ERR2 ESRRB
Estrogen-related receptor gamma ESRRG
Glucocorticoid receptor NR3C1

Referensi & Sumber

Synthesis reference: Daniella Gutman, Shimon Chernyak, "Process for preparing a crystalline form of halobetasol propionate." U.S. Patent US20070167420, issued July 19, 2007.
Artikel (PubMed)
  • PMID: 31334954
    Awad N, Preuss CV: Halobetasol Cream .
  • PMID: 30285357
    Yasir M, Sonthalia S: Corticosteroid Adverse Effects .
  • PMID: 23300763
    Gardill BR, Vogl MR, Lin HY, Hammond GL, Muller YA: Corticosteroid-binding globulin: structure-function implications from species differences. PLoS One. 2012;7(12):e52759. doi: 10.1371/journal.pone.0052759. Epub 2012 Dec 26.
  • PMID: 15634032
    Czock D, Keller F, Rasche FM, Haussler U: Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98. doi: 10.2165/00003088-200544010-00003.
  • PMID: 24347992
    Ciriaco M, Ventrice P, Russo G, Scicchitano M, Mazzitello G, Scicchitano F, Russo E: Corticosteroid-related central nervous system side effects. J Pharmacol Pharmacother. 2013 Dec;4(Suppl 1):S94-8. doi: 10.4103/0976-500X.120975.
  • PMID: 2349135
    Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L: The safety of halobetasol 0.05% ointment in the treatment of psoriasis. Pharmacotherapy. 1990;10(2):107-11.

Contoh Produk & Brand

Produk: 47 • International brands: 3
Produk
  • Bryhali
    Lotion • 0.1 mg/1g • Topical • US • Approved
  • Bryhali
    Lotion • 0.01 % w/w • Topical • Canada • Approved
  • Duobrii
    Lotion • - • Topical • US • Approved
  • Duobrii
    Lotion • - • Topical • Canada • Approved
  • Halobetasol Propionate
    Ointment • 0.5 mg/1g • Topical • US • Generic • Approved
  • Halobetasol Propionate
    Cream • 0.5 mg/1g • Topical • US • Generic • Approved
  • Halobetasol Propionate
    Ointment • 0.5 mg/1g • Topical • US • Generic • Approved
  • Halobetasol Propionate
    Cream • 0.5 mg/1g • Topical • US • Generic • Approved
Menampilkan 8 dari 47 produk.
International Brands
  • Halobetasol — Fougera
  • Halovate — Glenmark
  • Hobs — Aamorb

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul